US 12,479,828 B2
Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
Sangdon Han, San Diego, CA (US); Yunfei Zhu, San Diego, CA (US); Sun Hee Kim, San Diego, CA (US); Jian Zhao, San Diego, CA (US); and Shimiao Wang, San Diego, CA (US)
Assigned to CRINETICS PHARMACEUTICALS, INC., San Diego, CA (US)
Filed by Crinetics Pharmaceuticals, Inc., San Diego, CA (US)
Filed on Nov. 17, 2023, as Appl. No. 18/512,361.
Application 16/931,156 is a division of application No. 16/713,601, filed on Dec. 13, 2019, granted, now 10,766,877, issued on Sep. 8, 2020.
Application 16/713,601 is a division of application No. 16/432,228, filed on Jun. 5, 2019, granted, now 10,562,884, issued on Feb. 18, 2020.
Application 18/512,361 is a continuation of application No. 18/327,466, filed on Jun. 1, 2023, abandoned.
Application 18/327,466 is a continuation of application No. 18/065,446, filed on Dec. 13, 2022, abandoned.
Application 18/065,446 is a continuation of application No. 17/170,396, filed on Feb. 8, 2021, granted, now 11,566,015, issued on Jan. 31, 2023.
Application 17/170,396 is a continuation of application No. 16/931,156, filed on Jul. 16, 2020, granted, now 10,981,894, issued on Apr. 20, 2021.
Claims priority of provisional application 62/734,873, filed on Sep. 21, 2018.
Claims priority of provisional application 62/681,011, filed on Jun. 5, 2018.
Prior Publication US 2024/0300920 A1, Sep. 12, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/14 (2006.01); C07D 295/04 (2006.01); C07D 401/10 (2006.01); C07D 407/14 (2006.01)
CPC C07D 401/14 (2013.01) [C07D 295/04 (2013.01); C07D 401/10 (2013.01); C07D 407/14 (2013.01)] 22 Claims
 
1. A pharmaceutically acceptable salt of a compound of Formula (IX):

OG Complex Work Unit Chemistry
wherein:
V is CH;
X1 is N;
R2 and R3 are hydrogen;
or R2 and R3 are taken together with the carbon atom to which they are attached to form —C(═O)—;
Ra is —OCH2CH3;
Rb and Rc are hydrogen;
RB is

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
and wherein the pharmaceutically acceptable salt is selected from a chloride salt, a sulfate salt, a bromide salt, a mesylate salt, a maleate salt, a citrate salt, and a phosphate salt of a compound of Formula (IX).